This article was originally published in The Gray Sheet
Executive SummaryOptimal distribution method for Regeneration Technologies, Inc.'s Regenaform "moldable" maxillofacial bone paste is the only remaining item to be resolved after the companies work out a distribution agreement, effective Aug. 30. Exactech will serve as exclusive worldwide distributor for RTI-processed bone paste products for non-spinal musculoskeletal orthopedic procedures. The companies also will co-develop new bone paste products. The RTI/Exactech agreement is part of a settlement related to a 2001 arbitration ruling (1"The Gray Sheet" Jan. 7, 2002, In Brief)...
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.